| Item type |
文献 / Documents(1) |
| 公開日 |
2023-12-20 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/1759-7714.14775 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1111/1759-7714.14775 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib |
|
言語 |
en |
| 著者 |
國重, 道大
イチハラ, セイヤ
カドタ, ナオキ
オカノ, ヨシオ
マチダ, ヒサノリ
ハタケヤマ, ノブオ
ナルセ, ケイシ
篠原, 勉
タケウチ, エイジ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Lung cancer with complex epidermal growth factor receptor (EGFR) and CTNNB1 comutations is rare, and the efficacy of tyrosine kinase inhibitors (TKIs) is generally poor. Here, we encountered a lung cancer patient with complex EGFR (L858R and E709X) and CTNNB1 comutations who successfully responded to afatinib. A 78-year-old woman visited our hospital with a cough and bloody sputum that had worsened over the past year. She had multiple mass shadows in both lungs and nodular shadows in the bronchi. The patient was diagnosed with lung adenocarcinoma cT4N3M1c stage IVB. A genetic analysis of the primary tumor using the Oncomine Dx target test multi-CDx system revealed positivity for EGFR (L858R and E709X) and CTNNB1 mutations. The expression of programmed death ligand 1 (22C3 clones) in tumor cells was negative by immunostaining. The patient was treated with afatinib as first-line therapy and achieved clinical improvement and a partial response and is continuing treatment 1 year later. Case reports of lung cancer patients with EGFR/CTNNB1 comutations are rare, and TKIs are not considered to be effective. We herein present the first case report of lung cancer with the co-occurrence of uncommon and complex EGFR (L858R and E709X) and CTNNB1 mutations that was successfully treated with afatinib. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
afatinib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
CTNNB1 mutation |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
E709X |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
L858R |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
non–small cell lung cancer |
| 書誌情報 |
en : Thoracic Cancer
巻 14,
号 4,
p. 423-426,
発行日 2022-12-15
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597714 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597706 |
| 出版者 |
|
|
出版者 |
China Lung Oncology Group |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
John Wiley & Sons Australia |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| EID |
|
|
識別子 |
397278 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
tc_14_4_423.pdf (822 KB)
.png)
